The Med-Ex - EXCEMED Learning Group, in collaboration with the European Charcot Foundation (ECF) and AcademicCME, conducted a live, in presence course that was also accessible via online attendance.  This event was held prior to the ECTRIMS Congress.

This Programme took place at 9.30 (CEST), on 25th October, 2022. International experts addressed the main scientific breakthroughs in the field and provided practical suggestions for managing patients in clinical practice.

Overview

The field of Multiple Sclerosis (MS) is continuously evolving following the discovery of new pathogenetic mechanisms and new treatment targets. New evidence on MS epidemiology have renovated the interest in viral infections, in particular by Epstein-Barr virus, as main triggers of autoimmune attack to the central nervous system, opening the way for innovative treatment approaches. Recently, new drugs have been licensed for progressive forms of MS, highlighting the need for a more accurate classification of these forms and a better understanding of the mechanisms underpinning disability progression. 

The Pre-ECTRIMS workshop, stemming from a collaboration between EXCEMED-Med-Ex Learning Group, European Charcot Foundation and AcademicCME, aims to provide a yearly update on the main novelties in the most debated themes in the field of MS, through frontal lectures and open discussions involving experts from all over the world.

The workshop was open to in presence and online attendance. 

POST-EVENT RESOURCES

The slide kits and the video-lectures from this educational activity are available. Please click here to access the resources.

ACCREDITATION DETAILS

The 2022 joint pre-ECTRIMS workshop, Amsterdam, Netherlands, 25/10/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 4 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Endorsements

The 2022 Joint Pre-ECTRIMS Workshop, has been endorsed by ECTRIMS

Learning objectives

• Describe new immunological mechanisms underpinning MS
• Illustrate mechanisms of action and safety profile of new MS treatments
• Describe emerging environmental factors influencing MS development
• Discuss how to identify and monitor disability progression

AGENDA - Day 1 - October 25th, 2022

9.30 Welcome & Opening

G. Comi (Italy) and F. Lublin (USA)

Session 1: Understanding Multiple Sclerosis

Chair: G Comi (Italy)

9.45 L1 - Updated MS immunology

Bar-Or (USA)

10.05 L2 - New Diagnostic and prognostic aspects 

M. Tintorè (Spain)

10.25 L3 - Emerging treatments for relapsing and progressive MS 

G. Comi (Italy)

10.45 L4 - Remote monitoring in MS
L. Leocani (Italy)

11.05 Q&A

11.25 Coffee Break 

Session 2: Epstein-Barr virus in MS

Chairs: G Comi (Italy) and H. Lassmann (Austria)

11.45 L5 - Epidemiology 

A. Ascherio (USA)

12.05 L6 - Immunopathogenesis 

F. Aloisi (Italy)

12.25 L7 -  Possible interventions 

H. P. Hartung (Germany)

12.45 Q&A

13.05 Lunch 

Session 3: Controversies in Multiple Sclerosis Care
How MS Patients Develop Disability: Our New Understanding of the Role of Relapses and Progression

Chair: F D Lublin, (USA)

14.10 L8 - PIRA - What is it? How Does it Develop? 

L Kappos (Switzerland)

14.30 L9 - Developing Disability - Reassessing the Spectrum of MS

F.D. Lublin (USA)

14.50 L10 - Visualizing the Clinical Course of MS Over Time 

S. Krieger (USA)

15.10 L11 - Imaging Progressive Disease 

M. Inglese (Italy)

15.30        Q&A

INDUSTRY SUPPORTED SESSIONS

15.50    Scientific Update on Bruton Tyrosine Kinase Inhibitors to Improve Outcomes for Patients with Multiple Sclerosis

B.M. Greenberg (USA)

16.50   Strategies to Identify and Manage Spasticity and Related Symptoms in Patients with Multiple Sclerosis

F.D. Lublin (USA)

17.50   Wrap up

18.00 End of the day